Harnessing Nucleic Acids

We are an innovation-driven biotech company harnessing the power of nucleic acids to address major unmet medical needs.

We Leverage Nature's Most Versatile Material to Improve the Health of Millions of People

Nucleic acids are capable of encoding vast information and executing an array of biochemical functions.

We leverage the precise structural, functional, and information encoding capabilities of nucleic acids to unlock innovative medicines and diagnostic devices.

The right strategy for the right scaffold

We are the world-leading experts in nucleic acid-based diagnostics and therapeutics, backed by more than two decades of innovation.

Get Updated

Latest News
Aptitude has received multi-million dollars in funding in 2021.
Aptitude and Google jointly published machine learning-guided aptamer research on Nature Communications
Aptitude received California CLIA license for high-complexity molecular testing

Who We Are

Scott Ferguson, PhD

Scott Ferguson, PhD

CEO

To bring Aptitude's transformative value to market, Scott is responsible for customer development and strategic partnerships with industry leaders.

Jackson Gong, PhD

Jackson Gong, PhD

COO

Trained in both life science research and management, Jackson brings to Aptitude both scientific and operational expertise. He has published 10+ peer-reviewed papers and co-invented several patents that serve as the foundation of Aptitude technology.

JP Wang, PhD

JP Wang, PhD

CSO

As CSO, JP shapes the company’s technical vision and R&D strategy, while overseeing internal R&D programs, establishing R&D collaborations, and leading the team of scientists.